Time-to-progression after frontline chemoimmunotherapy for chronic lymphocytic leukemia: an independently validated retrospective cohort study

BACKGROUND: Because frontline treatment with FCR unequivocally improves progression-free and overall survival in CLL patients, it has become a “gold standard” for chemoimmunotherapy regimens. Follow-up studies show that a subset of generally young, physically-fit patients with mutated IGHV genes and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lancet Oncol
Hauptverfasser: Herling, Carmen D., Coombes, Kevin R., Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary B., Majewski, Tadeusz, Bondaruk, Jolanta E., Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan A., Oakes, Christopher, Ferrajoli, Alessandra, Keating, Michael J., Abruzzo, Lynne V.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7147008/
https://ncbi.nlm.nih.gov/pubmed/31582354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(19)30503-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge